1. A Quantitative Framework and Strategies for Management and Evaluation of Metabolic Drug-Drug Interactions in Oncology Drug Development

   • Karthik Venkatakrishnan
   • Michael D. Pickard
   • Lisa L. von Moltke

   Current Opinion 30 September 2012 Pages: 703 - 727

   

2. Pharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab

   • Bing-Bing Yang
   • Peggy Lum
   • Juan José Pérez Ruixo

   Review Article 30 September 2012 Pages: 729 - 740

   

3. Oseltamivir in Seasonal, Avian H5N1 and Pandemic 2009 A/H1N1 Influenza

   • Nicolas Widmer
   • Pascal Meylan
   • Thierry Buclin

   Review Article 30 September 2012 Pages: 741 - 765

   

4. Fluoxetine Disposition in Patients with Chronic Hepatitis C Treated with Interferon-α

   • Mario Furlanut
   • Giorgio Soardo
   • Loretta Franceschi

   Original Research Article 30 September 2012 Pages: 767 - 772

   

5. Plasma Anti-Xa Monitoring for Low-Molecular-Weight Heparins in Patients with Chronic Kidney Disease

   • Maurizio Gallieni
   • Alma Martini
   • Maria Fusaro

   Correspondence 30 September 2012 Pages: 773 - 774